Literature DB >> 56780

Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).

C A Alper, D Balavitch.   

Abstract

Evidence is presented that cobra venom factor, the anticomplementary protein in Naja naja venom, is modified cobra C3 (the third component of complement). Antiserum to the cobra venom factor cross reacts with human C3. A protein in cobra serum reacts strongly with antiserum to the venom factor and the former protein, like human C3, is converted by incubation of cobra serum with endotoxin, hydrazine, or simple storage at 37 degrees C. Incubation of cobra venom factor with cobra serum destroys the C3 cleaving activity of the venom factor in human serum, whereas human C3b inactivator is ineffective. Thus, the cobra venom factor appears to be a form of C3 (perhaps C3b); its potent action in human serum probably derives from its lack of sensitivity to human C3b inactivator.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56780     DOI: 10.1126/science.56780

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  26 in total

1.  Complement activation in acetaminophen-induced liver injury in mice.

Authors:  Rohit Singhal; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

2.  Complement components and lymphoid cell surfaces.

Authors:  I McConnell
Journal:  Proc R Soc Med       Date:  1976-09

3.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

4.  (p)ppGpp-Dependent Regulation of the Nucleotide Hydrolase PpnN Confers Complement Resistance in Salmonella enterica Serovar Typhimurium.

Authors:  N Y Elizabeth Chau; Deyanira Pérez-Morales; Wael Elhenawy; Víctor H Bustamante; Yong E Zhang; Brian K Coombes
Journal:  Infect Immun       Date:  2021-01-19       Impact factor: 3.441

5.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

6.  Molecular cloning and derived primary structure of cobra venom factor.

Authors:  D C Fritzinger; R Bredehorst; C W Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Flavoxobin, a serine protease from Trimeresurus flavoviridis (habu snake) venom, independently cleaves Arg726-Ser727 of human C3 and acts as a novel, heterologous C3 convertase.

Authors:  Chieko Yamamoto; Daisuke Tsuru; Naoko Oda-Ueda; Motonori Ohno; Shosaku Hattori; Sung-Teh Kim
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

8.  The acute effects of antiglomerular basement membrane antibody upon glomerular filtration in the rat. The influence of dose and complement depletion.

Authors:  R C Blantz; B J Tucker; C B Wilson
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

9.  Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.

Authors:  P J Baker; C J Parker; S G Osofsky
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

10.  Stimulation of complement production in mice by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine.

Authors:  N Endo; T Okuda; Y Osada; H Zen-Yoji
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.